Global Intravenous (IV) Iron Drugs In-Depth Industrial and Market studies Report: 2017 Edition
Albany, New York, Mar 01, 2017
"Global
Intravenous (IV) Iron Drugs Market Report: 2017 Edition"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Iron
is vital for multiple bodily functions, most importantly for the
production of hemoglobin for red blood cells which are responsible
for transporting oxygen in the blood. As an element, the only source
of iron is from the diet. There is no way the body can produce iron
itself. Intravenous (IV) treatment, in a broad sense, covers all the
types of medications delivered intravenously, i.e. directly into the
vein, through intravenous drip. Compared to the other routes of
infusing medications, the intravenous route is the fastest way to
deliver fluids and medications throughout the body. The first iron
product for intravenous use was high-molecular-weight iron dextran.
Some of the major areas of IV iron application include gynecology,
gastroenterology, oncology and surgeries.
Hemoglobin,
Ferritin, Transferrin, and Hepcidin are major molecules which are
critical in the function and regulation of iron.
The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.
The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.
The report analyzes the global iron products
industry along with an extensive coverage of global, Europe and the
US I.V. iron market. The global IV iron market witnesses intense
competition with numerous top notch players; such as Galenica
Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the
marketplace along with small budding players. As a part of analysis
of fierce competition prevailing in the industry, product contention
has been presented in the report. The company profiles of leading
aforementioned players in the market are also incorporated in the
report.
By combining SPSS Inc.’s data integration and
analysis capabilities with our relevant findings, we have predicted
the future growth of the industry. We employed various significant
variables that have an impact on this industry and created regression
models with SPSS Base to determine the future direction of the
industry. Before deploying the regression model, the relationship
between several independent or predictor variables and the dependent
variable was analyzed using standard SPSS output, including charts,
tables and tests.
Table
of Content
1. Iron in Human Body: An Introduction
1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.1 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment
1.4 Types of I.V. Iron
1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.1 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment
1.4 Types of I.V. Iron
2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
2.2 Global Iron Products Market Share by Segment
2.1 Global Iron Product Market by Value
2.2 Global Iron Products Market Share by Segment
3. Global I.V. Iron Drugs Market
Analysis
3.1 Global I.V. Iron Drugs Market by Value
3.2 Global I.V. Iron Drugs Market by Product
3.3 Global I.V. Iron Drugs Market Share by Product
3.1 Global I.V. Iron Drugs Market by Value
3.2 Global I.V. Iron Drugs Market by Product
3.3 Global I.V. Iron Drugs Market Share by Product
4. I.V. Iron Drugs Regional Market
Analysis
4.1 European I.V. Iron Drug Market
4.1.1 European I.V. Iron Drug Market by Value
4.1.2 European I.V. Iron Drug Market by Product
4.1.3 European I.V. Iron Drug Market Share by Product
4.2 The US I.V. Iron Drug Market
4.2.1 The US I.V. Iron Drug Market by Value
4.2.2 The US I.V. Iron Drug Market by Product
4.2.3 The US I.V. Iron Drug Market Share by Product
4.2.4 The US Non-dialysis I.V. Iron Drug Market by Volume
4.2.5 The US Non-dialysis I.V. Iron Drug Market Share by Product
4.1 European I.V. Iron Drug Market
4.1.1 European I.V. Iron Drug Market by Value
4.1.2 European I.V. Iron Drug Market by Product
4.1.3 European I.V. Iron Drug Market Share by Product
4.2 The US I.V. Iron Drug Market
4.2.1 The US I.V. Iron Drug Market by Value
4.2.2 The US I.V. Iron Drug Market by Product
4.2.3 The US I.V. Iron Drug Market Share by Product
4.2.4 The US Non-dialysis I.V. Iron Drug Market by Volume
4.2.5 The US Non-dialysis I.V. Iron Drug Market Share by Product
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increase in Number of Dialysis Cases
5.1.2 Increasing Healthcare Expenditure
5.1.3 Increasing Cases of CKD and ESRD
5.1.4 Rising Ageing Population
5.1.5 Shift from Rural to Urban Regions
5.1.6 Prevalence of Iron Deficiency in Women
5.1.7 Increasing Life Expectancy Rate
5.1.8 Rising Medicines Expenditures
5.1.9 Growing Number of ERSD Patients
5.2 Trends
5.2.1 New Product Development
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.2.3 Feraccru Treatment Penetration
5.3 Challenges
5.3.1 Emerging Anemia Management Therapies
5.3.2 Potential Risks of I.V. Iron
5.1 Growth Drivers
5.1.1 Increase in Number of Dialysis Cases
5.1.2 Increasing Healthcare Expenditure
5.1.3 Increasing Cases of CKD and ESRD
5.1.4 Rising Ageing Population
5.1.5 Shift from Rural to Urban Regions
5.1.6 Prevalence of Iron Deficiency in Women
5.1.7 Increasing Life Expectancy Rate
5.1.8 Rising Medicines Expenditures
5.1.9 Growing Number of ERSD Patients
5.2 Trends
5.2.1 New Product Development
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.2.3 Feraccru Treatment Penetration
5.3 Challenges
5.3.1 Emerging Anemia Management Therapies
5.3.2 Potential Risks of I.V. Iron
6. Competitive Landscape
6.1 Product Comparison
6.1 Product Comparison
7. Company Profiles
7.1 Galenica group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 AMAG Pharmaceuticals
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Allergan plc.
7.1 Galenica group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 AMAG Pharmaceuticals
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Allergan plc.
Comments
Post a Comment